IndraLab

Statements

Ruxolitinib inhibits STAT1-E545K. 1 / 1

| 1

reach

"Ruxolitinib inhibited in vitro T FH development in response to TGF-beta1, IL-12 and IL-23 leading to a number of CXCR5 + ICOS + T FH -like cells in the STAT1 E545K mutation that was comparable to the control prior to treatment (XREF_FIG)."

28139313

INDRA sources:

Colored badges next to statement headings correspond to evidence counts from knowledge sources, as shown below. Badges to the left of the | separator correspond to curated knowledge base sources, and badges to the right of it correspond to machine reading systems.

IndraLab

Statements

Ruxolitinib inhibits STAT1-E545K. 1 / 1

INDRA sources:

Databases

Reading